HER2-HER3 Heterodimer Quantification by FRET-FLIM and Patient Subclass Analysis of the COIN Colorectal Trial

Abstract Background The phase III MRC COIN trial showed no statistically significant benefit from adding the EGFR-target cetuximab to oxaliplatin-based chemotherapy in first-line treatment of advanced colorectal cancer. This study exploits additional information on HER2-HER3 dimerization to achieve...

Full description

Saved in:

Bibliographic Details
Published in:	JNCI : Journal of the National Cancer Institute Vol. 112; no. 9; pp. 944 - 954
Main Authors:	Barber, Paul R, Weitsman, Gregory, Lawler, Katherine, Barrett, James E, Rowley, Mark, Rodriguez-Justo, Manuel, Fisher, David, Gao, Fangfei, Tullis, Iain D C, Deng, Jinhai, Brown, Louise, Kaplan, Richard, Hochhauser, Daniel, Adams, Richard, Maughan, Timothy S., Vojnovic, Borivoj, Coolen, Anthony C C, Ng, Tony
Format:	Journal Article
Language:	English
Published:	United States Oxford University Press 01.09.2020
Subjects:	Adenocarcinoma - diagnosis Adenocarcinoma - metabolism Adenocarcinoma - mortality Adenocarcinoma - therapy Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bayes Theorem Capecitabine - therapeutic use Cohort Studies Colorectal Neoplasms - diagnosis Colorectal Neoplasms - metabolism Colorectal Neoplasms - mortality Colorectal Neoplasms - therapy Female Fluorescence Resonance Energy Transfer Humans Latent Class Analysis Male Microscopy - methods Middle Aged Oxaloacetates - therapeutic use Prognosis Protein Multimerization Randomized Controlled Trials as Topic - statistics & numerical data Receptor, ErbB-2 - analysis Receptor, ErbB-2 - metabolism Receptor, ErbB-3 - analysis Receptor, ErbB-3 - metabolism Tissue Array Analysis Treatment Outcome
ISSN:	0027-8874, 1460-2105, 1460-2105
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!